Auditors have raised doubts about the future viability of Central Pharmaceuticals Limited (pharmaceutical sector) and Sonargaon Textiles Limited (textile sector), both listed on the Dhaka Stock Exchange (DSE), following a review of their audited financial statements for the 2024-25 fiscal year.

According to DSE sources, Central Pharmaceuticals’ accounts were reviewed by Mohammad Shibbir Hossain, partner at Ashraf Uddin & Co. Chartered Accountants. The auditor noted that the company’s accumulated losses are almost equal to its paid-up capital, and management has failed to raise fresh funds. As a result, the company has defaulted on bank loans and faces significant tax demands from the National Board of Revenue (NBR). High costs and limited production have caused production expenses to exceed revenue, and the company has not renewed its drug license. Non-payment of DSE and CDBL fees also raises concerns about its future survival. Central Pharmaceuticals did not declare any dividend for 2024-25, posting a loss per share of Tk 0.18, compared to Tk 0.35 loss in the previous year. Its NAV per share stood at Tk 6.87 on June 30, and the share last traded at Tk 9.50 on the DSE, with a one-year trading range of Tk 7.10 to Tk 15.90.

Similarly, Sonargaon Textiles’ accounts were reviewed by A.K. Golam Kibria, partner at G Kibria & Co. Chartered Accountants. The auditor reported accumulated losses of Tk 15.85 crore, with shareholders experiencing negative returns in the review year, raising doubts about the company’s ability to continue operations. The company paid no dividend in 2024-25, reporting a loss per share of Tk 0.80, compared to a profit of Tk 0.27 per share in the previous year. Its NAV per share stood at Tk 18.35 on June 30, and the share last traded at Tk 32.20, with a one-year trading range of Tk 20.70 to Tk 52.00.